<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075187</url>
  </required_header>
  <id_info>
    <org_study_id>EFRONT 05-2021</org_study_id>
    <nct_id>NCT05075187</nct_id>
  </id_info>
  <brief_title>Epidemiological Study in FRONtoTemporal Dementia</brief_title>
  <acronym>EFRONT</acronym>
  <official_title>Epidemiological Study in FRONtoTemporal Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international, multicenter, epidemiological observational study aims to investigate the&#xD;
      prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for&#xD;
      FTD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous&#xD;
      neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal&#xD;
      and temporal lobes. This leads to abnormalities in behaviour, personality, and language&#xD;
      comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity,&#xD;
      difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or&#xD;
      heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial&#xD;
      aggregation). For this study, blood samples were collected from clinically diagnosed or&#xD;
      suspected FTD patients and were analysed for a broad range of pathogenic variants in genes&#xD;
      associated with FTD. The scientific insights acquired from this study will help identify&#xD;
      novel therapeutic targets and develop/ investigate potential disease-modifying drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Participants diagnosed with Frontotemporal Dementia</arm_group_label>
    <description>Participants diagnosed with Frontotemporal Dementia</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genetic Screening</intervention_name>
    <description>Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.</description>
    <arm_group_label>Participants diagnosed with Frontotemporal Dementia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants diagnosed with Frontotemporal Dementia (FTD) and participants clinically&#xD;
        suspected for FTD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent, which includes reference to the genetic testing, is obtained from&#xD;
             the participant/legal guardian&#xD;
&#xD;
          -  The participant is aged between 25 to 85 years&#xD;
&#xD;
          -  The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or&#xD;
             symptoms of FTD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jefri Jeya Paul, Ph.D</last_name>
    <phone>+49 381 80113 543</phone>
    <email>Jefri.Paul@centogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanau Hospital</name>
      <address>
        <city>Hanau</city>
        <state>Hessen</state>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

